Clinical trials: Tumor Pancreas
Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Metastatic Pancreatic Cancer
The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial
The goal of this clinical trial is to evaluate the effectiveness and safety of hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy in peritoneal metastatic pancreatic cancer.
- Trial name
- NCT06946901
- Testing
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Benign Breast Disease, Breast Cancer
Prolactin Receptor and Breast Diseases
Prolactin is known to play an important role in breast development and differentiation. Thus proliferative breast diseases are good models to unravel PRl / PRLR function in proliferative processes.
- Trial name
- Prolacsein (NCT00842465)
- Testing
- blood collection for hormonal status analysis, breast Biopsy or surgery, blood collection
- Where
- France
- Volunteers
- 735 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and dasatinib when given together with erlotinib hydrochloride in treating patients with pancreatic cancer that has spread to other places in…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT01660971
- Testing
- Dasatinib, Erlotinib Hydrochloride, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable…
- Trial name
- NCT00243854
- Testing
- Tarceva
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
Pancreas Cancer, Lung Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases
- Trial name
- NCT04115254
- Testing
- MR-guided Linac
- Where
- 2 sites in United States
- Volunteers
- 397 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasm
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer.
- Trial name
- NCT00226005
- Testing
- PTK787/ZK222584
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Pancreatic Cancer Research Team
CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
To explore the possibility to overcome CYP3A-mediated resistance to anticancer drugs in pancreatic cancer, we will investigate the pharmacokinetics, safety, tolerability, and efficacy of nanoparticle albumin-bound paclitaxel…
- Conditions
- CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- IntenSify (NCT05494866)
- Testing
- Cobicistat Oral Tablet, Gemcitabin, Nab paclitaxel
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- German Cancer Research Center
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum…
- Trial name
- POLO (NCT02184195)
- Testing
- Olaparib
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without capecitabine in treating pancreatic…
- Trial name
- NCT00032175
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 30 sites in United Kingdom
- Volunteers
- 508 people
- Sponsor
- Cancer Research UK
Neuroendocrine Carcinomas
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
Poorly differentiated neuroendocrine carcinomas (NEC) are a sub-group of aggressive neuroendocrine neoplasms (NEN). The most common primary sites are broncho-pulmonary and digestive.
- Trial name
- BEVANEC (NCT02820857)
- Testing
- Folfiri-bevacizumab, Folfiri
- Where
- 26 sites in France
- Volunteers
- 153 people
- Sponsor
- Hospices Civils de Lyon
Stage IV Pancreatic Cancer
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).
- Trial name
- NCT01893801
- Testing
- nab-paclitaxel, Cisplatin, gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Pancreatic Cancer Research Team
Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.
- Trial name
- NCT04721301
- Testing
- Nivolumab plus Ipilimumab plus Maraviroc
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Heidelberg
Pancreatic Cancer
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with or without chemotherapy and chemoradiation.
- Trial name
- NCT00614601
- Testing
- HyperAcute(R)-Pancreatic Cancer Vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NewLink Genetics Corporation
Pancreatic Cancer, Ovarian Cancer
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.
- Conditions
- Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
- Trial name
- NCT05922930
- Testing
- TROP2-CAR-NK, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Advanced Cancer, Gastric Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- Minnelide 101 (NCT03129139)
- Testing
- Minnelide™Capsules
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Minneamrita Therapeutics LLC
Pancreatic Cancer, Metastasis
Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
This is an interventional, open-label, non-randomised, multicentre, single-arm phase II clinical trial. Eligible patients with hepatic oligometastatic adenocarcinoma of the pancreas will receive neoadjuvant combination…
- Conditions
- Pancreatic Cancer, Metastasis, Surgery, Oligometastatic Disease
- Trial name
- HOLIPANC (NCT04617457)
- Testing
- nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)
- Where
- 11 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University of Cologne
Colorectal Cancer, Epithelial Ovarian Cancer
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of [68Ga]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC)…
- Conditions
- Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer (GC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07702292
- Testing
- [68Ga]BED003
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 71 people
- Sponsor
- Blue Earth Diagnostics
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Pancreatic Cancer
Pancreatic Cancer Lifestyle Evolution And Resistance
Advanced PDAC patients undergo polychemotherapy, yet responses are highly variable. Transcriptome signatures are emerging as key predictors of treatment response. However, PDAC adapts across sites (primary vs.
- Trial name
- CLEAR (NCT07794969)
- Testing
- Endoscopic Ultrasound with FNA/FNB
- Volunteers
- 150 people
- Sponsor
- IRCCS San Raffaele
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.